| abstract |
The present invention relates to a humanized monoclonal antibody or fragment thereof that specifically binds to human interleukin-2 (IL2), wherein the humanized monoclonal antibody binds to human IL2-receptor before binding to human IL2-receptor. And / or neutralize the activity of human IL2 by binding to human IL2 after binding, wherein the light chain variable region of the humanized monoclonal antibody comprises the amino acid sequence KAPKA adjacent to amino acid positions 42-46 in its second framework region. . |